RxDoctor Payments Data

Farrukh Anwar, MD

Internal Medicine · Caro, MINPI 1144268947

Payments from drug & device makers

$1,588in general payments, 2019–2025

Across 92 payments — averaging $17.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$561
  • Novartis$243
  • Amgen$226
  • GSK$97
  • AstraZeneca$93
  • Novo Nordisk$66
  • plus $302 from 11 others

What the payments were for

  • Food & beverage$1,54497%
  • Education$443%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,588 in reported general payments places this provider in the 80th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$255,613
Medicare patients
449
Services billed
4,479

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept43$305,835
EnbrelEtanercept34$286,436
EliquisApixaban320$199,216
Humira(Cf) PenAdalimumab24$161,234
Humira PenAdalimumab19$128,136
Cimzia (2 Pack)Certolizumab Pegol16$97,449
TrulicityDulaglutide81$97,082
JanuviaSitagliptin Phosphate125$88,875
OzempicSemaglutide51$86,404
JardianceEmpagliflozin139$84,289
MyrbetriqMirabegron87$46,244
XareltoRivaroxaban61$43,329
MounjaroTirzepatide29$41,227
EntrestoSacubitril/Valsartan46$31,645
NuedextaDextromethorphan Hbr/Quinidine27$18,412

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenEnbrel$226$286,43634 claims
PfizerEliquis$44$199,216320 claims
Novo NordiskOzempic$66$86,40451 claims
Astellas Pharma US IncMyrbetriq$11$46,24487 claims
Johnson & JohnsonXarelto$49$43,32961 claims
NovartisEntresto$243$31,64546 claims
GSKTrelegy Ellipta, Breo Ellipta, Arexvy$97$25,62450 claims
AstraZenecaBreztri Aerosphere, Farxiga$93$25,46032 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Caro

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →